Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer (Rexochir)

March 12, 2026 updated by: Centre Jean Perrin
This randomized controlled trial will evaluate the effect of a preoperative rehabilitation program at home in patients resected for lung cancer, comparing a control group (C group) receiving only chest physiotherapy and a rehabilitation group (R group) receiving both a training program at home and chest physiotherapy

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Clermont-Ferrand, France, 63011
        • Centre Jean Perrin
      • Clermont-Ferrand, France, 63000
        • CHU Clermont Ferrand, Gabriel Montpied, service de médecine du sport et explorations fonctionnelles,
      • Clermont-Ferrand, France, 63009
        • Centre de Recherche en Nutrition Humaine
      • Grenoble, France, 38700
        • CHU Grenoble, Hôpital Michallon
      • Lyon, France, 69677
        • Hospices Civiles de Lyon, groupement hospitalier Est, Hopital Louis Pradel
      • Saint-Etienne, France, 42055
        • CHU Saint-Etienne, CHU Hopital Nord

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients diagnosed for lung cancer (or highly suspicious for cancer tumor) eligible for resection surgery (lobectomy or pneumonectomy)
  • Age > 18 years
  • Presence of Chronic Obstructive Pulmonary Disease (COPD) stages 2-4 of Gold (forced expiratory volume (FEV )/ forced vital capacity (FVC) <70%, FEV <80% of predicted) and Exertional dyspnea stage MMRC (Medical Research Council) > 1
  • Patients must provide written consent
  • Member of social security scheme

Exclusion Criteria:

  • Patients refusing to participate
  • COPD stage 1 Gold (VEMS >= 80% of the theoretical value)
  • Presenting an operating contraindication during the initial maximal exercise test
  • Presenting cardiac or vascular contraindication to achieve the readaptation program
  • Patient living alone at home
  • Patient with ventilatory assistance at home (oxygen therapy or noninvasive ventilation (NIV))
  • With exercise hypoventilation (PaCO2 >45 mmHg)
  • Cognitive difficulty
  • unable major
  • pregnancy,
  • patients deprived of liberty by a court or administrative decision

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: control group (C group)
patient will receive preoperative chest physiotherapy (standard supportive care)
Other: preoperative chest physiotherapy
preoperative chest physiotherapy : 5 sessions per week during 3 weeks
Experimental: rehabilitation group (R group)
patient will receive preoperative chest physiotherapy and a preoperative rehabilitation program at home (exercise training)
Other: preoperative chest physiotherapy
preoperative chest physiotherapy : 5 sessions per week during 3 weeks
Other: preoperative rehabilitation program
exercise training at home : 5 sessions per week during 3 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hospital length of stay after resection for lung cancer
Time Frame: time from the date of the surgery (Day 0) until the date of discharge (Day n) (assessed up to 56 days)
the date of discharge will be the real day of discharge from surgery department or the day where the patient will be medically considered as outgoing
time from the date of the surgery (Day 0) until the date of discharge (Day n) (assessed up to 56 days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the number of complications
Time Frame: during the stay in the surgery department or the intensive care unit (up to 56 days)
during the stay in the surgery department or the intensive care unit (up to 56 days)
peak oxygen consumption
Time Frame: evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)

evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).

evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5)
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)
6 minutes walking distance
Time Frame: evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)

evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).

evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5)
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)
maximal voluntary quadriceps strength
Time Frame: evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)

evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).

evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5)
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)
maximal inspiratory and expiratory strength
Time Frame: evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)

evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).

evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5)
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)
real length of stay
Time Frame: between the first postoperative day (Day 1) and the real discharge date (up to 56 days)
the real day of discharge from surgery department
between the first postoperative day (Day 1) and the real discharge date (up to 56 days)
body composition (bioimpedancemetry)
Time Frame: evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)

evaluation N°1 before intervention : during the week before the first date of the intervention (week 1) (intervention : preoperative chest physiotherapy +/- rehabilitation program will be realized on weeks 2, 3, and 4).

evaluation N°2 after intervention and before surgery : during the week before the date of surgery (week 5)
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2: during the week before the date of surgery (week 5)
oxidative adaptations of the muscle
Time Frame: evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2 after intervention : at the date of surgery (during the surgical time at Day 0 week 6)
optional ancillary study on quadricipal and intercostal muscle biopsies.
evaluation N°1 : during the week before the first date of the intervention (week 1). evaluation N°2 after intervention : at the date of surgery (during the surgical time at Day 0 week 6)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Jean Perrin

Investigators

  • Principal Investigator: Marc FILAIRE, Pr, Centre Jean Perrin

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 12, 2017

Primary Completion (Actual)

February 13, 2026

Study Completion (Actual)

February 13, 2026

Study Registration Dates

First Submitted

December 20, 2016

First Submitted That Met QC Criteria

January 12, 2017

First Posted (Estimated)

January 13, 2017

Study Record Updates

Last Update Posted (Actual)

March 13, 2026

Last Update Submitted That Met QC Criteria

March 12, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2016-A00622-49

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lungcancer

Clinical Trials on preoperative chest physiotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe